Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry

Ceccato, Attilio; Klinkenberg, Régis; Hubert, Philippe; Streel, Bruno

doi:10.1016/s0731-7085(03)00169-9

Cited by 69 publications

(51 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Lower LOQs for BUP were achieved in procedures by determining fewer analytes, and therefore allowing for longer dwell times, 21,23,25,26,56,57 by applying a stronger ionization using an APCI interface (atmospheric pressure chemical ionization) 21,57 or by using equivocal MRM transitions with the same parent and daughter ion masses of BUP. 19,23,25 Other groups prefer GC/MS procedures for the analysis of BUP. 14,22 An important aim of the present work was to achieve good chromatographic separation of HYD and MOR, as well as the separation of M3G and M6G.…”

Section: Discussionmentioning

confidence: 99%

An automated and fully validated LC‐MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites

Mußhoff¹,

Trafkowski²,

Kuepper³

et al. 2006

J. Mass Spectrom.

113

View full text Add to dashboard Cite

A fully validated liquid chromatographic procedure coupled with electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) is presented for quantitative determination of the opioids buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, oxymorphone, piritramide, tilidine, and tramadol together with their metabolites bisnortilidine, morphine-glucuronides, norfentanyl, and nortilidine in blood plasma after an automatically performed solid-phase extraction (SPE). Separation was achieved in 35 min on a Phenomenex C12 MAX-RP column (4 microm, 150 x 2 mm) using a gradient of ammonium formiate buffer (pH 3.5) and acetonitrile. The validation data were within the required limits. The assay was successfully applied to authentic plasma samples, allowing confirmation of the diagnosis of overdose situations as well as monitoring of patients' compliance, especially in patients under palliative care.

show abstract

Section: Discussionmentioning

confidence: 99%

An automated and fully validated LC‐MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites

Mußhoff¹,

Trafkowski²,

Kuepper³

et al. 2006

J. Mass Spectrom.

113

View full text Add to dashboard Cite

show abstract

“…5 and liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry (LC/APCI-MS/MS). 6 method including BUP, NBUP and buprenorphine-3-ˇ-Dglucuronide (BUP-3-G) in human plasma was developed using LC/ESI-MS/MS. 7 Ceccato et al 6 and Polettini and Huestis 7 quantified BUP and NBUP using the transition of the precursor mass to the precursor mass in quadrupole three of the triple-quadrupole mass spectrometer.…”

Section: Introductionmentioning

confidence: 99%

Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine‐3‐β‐D‐glucuronide and norbuprenorphine‐3‐β‐D‐glucuronide in human plasma

Murphy

Huestis

2005

J. Mass Spectrom.

View full text Add to dashboard Cite

A liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of the synthetic opiate buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine-3-beta-D-glucuronide (BUP-3-G) and norbuprenorphine-3-beta-D-glucuronide (NBUP-3-G) in human plasma was developed and validated. Identification and quantification were based on the following transitions: m/z 468 to 396 and 414 for BUP, m/z 414 to 326 and 340 for NBUP, m/z 644 to 468 for BUP-3-G and m/z 590 to 414 for NBUP-3-G. Calibration by linear regression analysis utilized deuteratated internal standards and a weighting factor of 1/x. The method was accurate and precise across a linear dynamic range of 0.6-50.0 ng ml(-1). Pretreatment of plasma samples using solid-phase extraction was sufficient to limit matrix suppression to <30% for all four analytes. The method proved to be suitable for the quantification of BUP and the related metabolites in plasma samples collected from BUP-maintained study participants.

show abstract

“…Full validation and application were well performed in the study; however, according to this study, naloxone with LLOQ of 0.1 ng mL -1 is not sensitive enough to enable pharmacokinetics profiling since it has low bioavailability. Moreover, a low dose of BUP administered sublingually resulted in a range of BUP hard to detect in the plasma [25,26]. Many limitations due to biological samples still remain.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma by LC-MS-MS

Chiang

Pao²,

Hsiong³

et al. 2011

Chromatographia

View full text Add to dashboard Cite

A novel sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS-MS) method simultaneously determined buprenorphine (BUP) and its active metabolite, norbuprenorphine (NBUP), and a coformulant, naloxone was developed, validated and applied successfully in humans. Buprenorphine-d 4 and norbuprenorphine-d 3 were used as the internal standard. The analysis was performed on a silica column, and the mobile phase was isocratic and composed of acetonitrile:2 mM ammonium formate in H2O (82:18, v/v). Mass spectrometry employed multiple reaction monitoring modes with transitions of m/z 468.1-55.2 for BUP, 414.2-101.2 for NBUP, 328.3-310.3 for naloxone, 472.1-59.2 for buprenorphine-d 4 and 417.2-101.2 for norbuprenorphine-d 3 . Lower limit of quantification (LLOQ) of the analytical method was 0.05 ng mL -1 for BUP, 0.1 ng mL -1 for NBUP and 0.025 ng mL -1 for naloxone, respectively. The standard calibration curves of BUP, NBUP and naloxone were linear over the concentration range of 0.05-20 ng mL -1 , 0.1-20 ng mL -1 and 0.025-20 ng mL -1 , respectively. The precisions (RSD) and accuracies (RE) of LLOQ and other QC samples were in acceptable range, with RSD \ 20% and RE ± 20% for LLOQ and RSD \ 15% and RE within ±15% for QC samples. The method was accurate, precise and specific, and was applied to the pharmacokinetic study of buprenorphine in healthy volunteers.

show abstract

Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry

Cited by 69 publications

References 38 publications

An automated and fully validated LC‐MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites

An automated and fully validated LC‐MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites

Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine‐3‐β‐D‐glucuronide and norbuprenorphine‐3‐β‐D‐glucuronide in human plasma

Simultaneous Determination of Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma by LC-MS-MS

Contact Info

Product

Resources

About